The progression of pancreatic carcinogenesis arises from low‐grade dysplasia carrying KRAS mutation to high‐grade invasive carcinomas when TP53 mutations have occurred, with intermediate stages involving inactivation of CDKN2A and SMAD4. Emerging strategies are being developed to target these genes. This evidence concerns the gene SMAD4 and carcinoma.